# p53 Vaccine for Ovarian Cancer

> **NCT00001827** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 21 (actual)

## Conditions studied

- Ovarian Neoplasm

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** incomplete Freund's adjuvant
- **BIOLOGICAL:** p53 peptide vaccine
- **BIOLOGICAL:** sargramostim
- **BIOLOGICAL:** therapeutic autologous dendritic cells
- **PROCEDURE:** in vitro-treated peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00001827
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-07-26
- **Primary completion:** 2007-12-17
- **Final completion:** 2013-01-25
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00001827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00001827, "p53 Vaccine for Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00001827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*